Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis
Daniel Isufi, Mikkel Bak Jensen, Nikolai Loft, Lone Skov, Jesper Elberling, Farzad Alinaghi
Abstract
= .0097]). Remarkably, an increased risk of herpes zoster infections was found in dermatologic indications but not in nondermatologic indications. In conclusion, we identified a significantly increased risk of developing infections during treatment with oral JAK inhibitors compared to placebo across indications. In sub-analyses, we additionally found an increased risk of herpes zoster in dermatologic indications.
Topics & Concepts
MedicinePlaceboJanus kinaseRandomized controlled trialMeta-analysisInternal medicineSystematic reviewJanus kinase inhibitorPharmacologyIntensive care medicineMEDLINEAlternative medicinePathologyBiologyBiochemistryCytokineCancer Treatment and PharmacologyChemotherapy-related skin toxicityHER2/EGFR in Cancer Research